Navigation Links
Regeneron Announces February 2012 Investor Conference Presentations
Date:2/21/2012

TARRYTOWN, N.Y., Feb. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:

  • Citi 2012 Global Healthcare Conference at 3:00 p.m. Eastern Time on Tuesday, February 28, 2012
  • RBC Capital Markets' Healthcare Conference at 9:00 a.m. Eastern Time on Wednesday, February 29, 2012
  • The sessions may be accessed through the Company's web site, www.regeneron.com, on the Events and Presentations page.  Archived versions of the presentations will be available for thirty days after the live webcasts. 

    Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA® (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:  

     Manisha Narasimhan, Ph.D.

    Peter DworkinInvestor Relations

    Corporate Communications914-847-5126

    914.847.764manisha.narasimhan@regeneron.com

    peter.dworkin@regeneron.com


    '/>"/>
    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
    2. Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
    3. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
    4. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
    5. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
    6. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
    7. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
    8. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
    9. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
    10. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
    11. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/5/2016)... --> --> ... the global active pharmaceuticals ingredients (APIs) market stood at ... US$185.9 bn by 2020. It is expected to expand ... The title of the report is "Active Pharmaceutical Ingredients ... by Therapeutic Area) - Global Industry Analysis, Size, Share, ...
    (Date:2/5/2016)... WARSAW, Ind. , Feb. 5, 2016  Zimmer ... the pricing of the previously announced underwritten secondary offering ... of its stockholders, consisting of affiliates of Blackstone and ... public at an initial price of $96.45 per share. ... of the offering.  Neither Zimmer Biomet nor any of ...
    (Date:2/5/2016)... 5, 2016  Henry Schein, Inc. (NASDAQ: HSIC ), ... services to office-based dental, animal health and medical practitioners, ... to acquire a majority ownership interest in Dental Cremer ... Brazil . ... Cremer is the dental distribution business of Cremer S.A. ...
    Breaking Medicine Technology:
    (Date:2/8/2016)... Las Vegas, Nevada (PRWEB) , ... February 08, ... ... Co-Founder at RowdMap, Inc., will be speaking on how healthcare companies can use ... project costs, manage the health of a population and intervene and capture the ...
    (Date:2/7/2016)... ... 07, 2016 , ... Women's Excellence staff, in all four locations, wore red ... Red Day is the first Friday each February and a day to bring attention ... 3 deaths among women each year – more than all cancers combined. Go Red ...
    (Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX ... warm color grades to their footage. A LUT is a Lookup Table that contains ... the corresponding color indicated by the table. By manipulating each pixel, LUT's can change ...
    (Date:2/5/2016)... ... February 05, 2016 , ... ... the company's lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability ... in design and manufacturing not only reduce the weight of the unit, they ...
    (Date:2/5/2016)... Rosa, CA (PRWEB) , ... February 05, 2016 ... ... pleased to announce the addition of micro-needling services in their Napa Valley office. ... The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part ...
    Breaking Medicine News(10 mins):